Prof. Dr. Alireza Heidari, Ph.D., D.Sc. is a Full Professor and Academic Tenure of Chemistry at California South University (CSU), Irvine, California, USA. He has got his Ph.D. and D.Sc. degrees from California South University (CSU), Irvine, California, USA. Furthermore, he has double postdocs in Project Management, Oncology, Human Cancer Tissues and Synchrotron Radiation from Monash University, Melbourne, Victoria, Australia and also in Nanochemistry and Modern Molecular Electronic–Structure Computations Theory from California South University (CSU), Irvine, California, USA. His research interests include Biophysical Chemistry, Biomolecular Spectroscopy, Quantum Chemistry, Nanochemistry, Modern Electronic Structure Computations, Theoretical Chemistry, Mathematical Chemistry, Computational Chemistry, Vibrational Spectroscopy, Molecular Modelling, Ab initio & Density Functional Methods, Molecular Structure, Biochemistry, Molecular Simulation, Pharmaceutical Chemistry, Medicinal Chemistry, Oncology, Synchrotron Radiation, LASER, Anti–Cancer Nano Drugs, Nano Drugs Delivery, ATR–FTIR Spectroscopy, Raman Spectroscopy, Intelligent Molecules, Molecular Dynamics, Biosensors, Biomarkers, Molecular Diagnostics, Numerical Chemistry, Nucleic Acids, DNA/RNA Monitoring, DNA/RNA Hypermethylation & Hypomethylation, Human Cancer Tissues, Human Cancer Cells, Tumors, Cancer Tissues, Cancer Cells, etc. He has participated at more than three hundreds reputed international conferences, seminars, congresses, symposiums and forums around the world as yet. Also, he possesses many published articles in Science Citation Index (SCI)/International Scientific Indexing (ISI) Journals. It should be noted that he has visited many universities or scientific and academic research institutes in different countries such as United States, United Kingdom, Canada, Australia, Scotland, Ireland, Netherlands, Belgium, Denmark, Greece, Russia, Estonia, Turkey, France, Swiss, Germany, Sweden, Norway, Italy, Austria, Czech Republic, Hungary, Poland, South Africa, Egypt, Brazil, Spain, Portugal, Mexico, Japan, Singapore, Malaysia, Thailand, Taiwan, Hong Kong, South Korea, China, India, Qatar, United Arab Emirates, etc. as research fellow, sabbatical and volunteer researcher or visitor and so on heretofore. He has a history of several years of teaching for college students and various disciplines and trends in different universities. Moreover, he has been a senior advisor in various industry and factories. He is expert in many computer programs and programming languages. Hitherto, he has authored more than twenty books and book chapters in different fields of Chemistry. Syne, he has been awarded more than nine hundreds reputed international awards, prizes, scholarships and honors. Heretofore, he has multiple editorial duties in many reputed international journals, books and publishers. Hitherward, he is a member of more than three hundreds reputed international academic–scientific–research institutes around the world. It should be noted that he is currently the President of American International Standards Institute (AISI), Irvine, California, USA and also Director of the BioSpectroscopy Core Research Laboratory at California South University (CSU), Irvine, California, USA.
Dr. HuAis graduated in 1973 from the University of La Plata School of Medicine, Argentina. His postgraduate training in Internal Medicine was completed at Ramos Mejia Hospital in Buenos Aires, Argentina. Fellowships in Medical Oncology were completed at the Universidad del Salvador and Chair of Oncology based at the Central Military Hospital, Buenos Aires, Argentina. He completed his oncology fellowship at the Miami Cancer Institute, Florida, USA. He is Assistant Professor of Internal Medicine at the University of Buenos Aires. He is Head Professor of Oncology and Course Director of Oncology at Maimonides University School of Medicine. Since 1983 he has been Medical Director and Chief of Medical Oncology, Centro Oncologico Buenos Aires (COBA). Since 1996, Dr Hunis has been an Associate Investigator in the ATLAS study, Oxford University and principal clinical investigator in multicenter studies of Phase II and Phase III breast cancer, lung, melanoma, and cancer-related pain.
Dr. Chen Hsiung Yeh received his Ph.D. in Microbiology and Molecular Genetics from Rutgers University, and completed his post-doctoral training at Washington University School of Medicine at St. Louis. He has more than 20 years of experience in the biotech pharmaceutical and diagnostic clinical laboratory service industries. Currently, he is co-founder and Chief Scientific Officer at Circulogene Theranostics. He has held senior management positions in various companies including Vice President of Molecular Testing at Atherotech Diagnostics Lab; General Manager at Response Genetics; Scientific Director at Quest Diagnostics; and Principal Investigator at Pfizer. His expertise and experience includes drug discovery, molecular diagnostics, oncology and advanced technology. He is the author and inventor of more than 40 publications and patents.
Cancer Biomarker Discovery; Noninvasive Cancer Early Detection; Disease Diagnosis and Prognosis; Liquid Biopsy; Digital Droplet PCR
Dr. Mendoza completed his medical school in the Catholic University (Ecuador) and his certification in medical oncology from Autonomous University of Barcelona (Spain). He completed his residency in Medical Oncology at the Santa Creu i Sant Pau Hospital in Barcelona, Spain. As a physician, he has an extensive record with the treatment of bad-prognosis cancer patients with high-dose chemotherapy and bone marrow transplantation. He continued with his PhD studies in the field of immunology-oncology at the Academy of Sciences in Prague where he worked in different types of anticancer vaccines and became an expert in the field of dendritic- cell based vaccines in experimental models.
Dr. Luis Mendoza has a position of Senior Medical Director within the Oncology Global Therapeutic Delivery Unit of QuintilesIMS. He has served as Medical and Scientific Advisor on many different clinical trials in the following indications: Breast Cancer, Ovarian Cancer, Cancer Related Anaemia, Non-Small Cell Lung Cancer, Hodgkin Disease, Non-Hodgkin Lymphomas, Acute Myeloid Leukaemia, Chronic Lymphocytic Leukaemia, Prostate Cancer, Head and Neck Cancer, Colon-Rectal Cancer, Bladder Cancer, Advanced Solid Tumours and Advanced Hematologic Malignancies. He has great expertise in clinical pharmacology acquired after a record of more than 40 phase I clinical trials. He has overseen several oncology and non-oncology global drug development programs. Prior to joining Quintiles IMS in January 2015, Dr. Luis Mendoza acquired 20+ years of haematology and oncology experience in the oncology medical practice combined with 13+ years of experience in clinical development of different oncology and general medical use compounds. Dr Mendoza has 9+ years in hem-oncology trials testing different anticancer compounds like targeted therapies, immunotherapy’s, oncolytic virus vaccines, antibody-drug conjugated vaccines, chemotherapies, PARP inhibitors and antiangiogenic drugs. Dr Mendoza continues with his altruistic unpaid labour as a consultant for physicians or cancer patients. He is author and co-author of several medical and scientific publications in peer review journals and author of educational manuals in cancer.
Adama Ly is the President - Founder of AFROCANCER, an international network against cancer in Africa. He is also the Founder in 2009 and editor in chief of the revue “Journal Africain du Cancer/ African Journal of Cancer” published by Springer France. Adama Ly is Doctor in Immunology and Oncology at University Paris XI and was member of the Doctoral school of Gustave Roussy cancer Institute (Villejuif, France). Dr. Ly received a degree in Biomedical Engineering and Innovations Management (Pierre and Marie Curie University, Paris, France). He graduated in Master of Social Health (MSH) from Ecoles des Hautes Etudes en Sciences Sociales (School of High studies in social Sciences) (Paris). He was visiting fellow at Sydney Kimmel Cancer Center (SKCC, San Diego, California, USA) and at Martin Luther Wittenberg University (Halle, Germany).
As senior manager in medical and fundamental researches, he focuses his work in growth factors and antitumor immunity and cellular therapies of tumours at INSERM (National Institute for Health and Medical Research) and University Paris XI.As a promoter of the fight against cancer in Africa, we was the co-editor of the book “About cancer in Africa, from Epidemiology to biomedical applications and perspectives” a multidisciplinary book with 136 authors from 32 countries worldwide, published by the French National cancer Institute. Preface of Pr. Jean Dausset, medicine Nobel Prize owner.As Lead coordinator in Health and development, Dr. Ly is conducting a project aiming to build a Center for Cancer Prevention and research in Senegal to help reducing the impact of cancer in African populations and to boost knowledge and exchanges between develop and developing countries.
Dr. Ly has received international awards (Laureate of the 2011 Editorial Award attributed by the Syndicate of Health profession’s publishers and medias (Paris 20 October 2011), was elected « Men of Year 2007 » with 14 other laureates by African medias and congratulations and Honours of International Atomic Energy Agency (IAEA), Vienna, Austria ( 20 September 2007)
Member of many professional societies and scientific boards, he has published several articles and books in cancer research and development.
Antitumoral immunity Cellular therapies of tumours; Cancer in developing countries; Social health and Sciences; Innovations management; Global health.
Dr. Serap Yalçın is currentlyworking as an AssociateProfessor in theFaculty of MolecularBiologyand Genetics, Ahi Evran University, Turkey. Shereceived her M.S. andPh.D. degreefromForensicScienceInstitute, Ankara University. She completed her postdoctoral training at Department of BiologicalSciences, Middle East Technical University and Klinikumrechts der Isar, Technische Universitat Müchen.Her research is focused on cancer molecular biology, Targeted drug delivery in cancer, Molecular pharmacology and toxicology. She has scientific membership at EACR.
Cancer molecular biology; Targeted drug delivery in cancer; Molecular pharmacology and toxicology
Rong Liu is one of the surgeons who firstly perform robotic assisted surgery in China, and has finished more than 1750 cases of robotic assisted HBP surgery, including more than 450 cases of robotic pancreaticoduodenectomy, and 1000 cases of robotic pancreatectomy. Perform 600 cases of hepatopacreatobiliary surgery every year, 70% of which were complicated surgery such as hemihepatectomy, pancreatoduodenectomy, radical hilar cholangiocarcinoma resection, radical gallbladder carcinoma resection, distal pancreatectomy and so on .He has rich experience in the surgical treatment of hepatopancreatobiliary tumors, published 137 papers as the first or corresponding author,reported a lotof cases of novel and modified operations, including laparoscopic hemihepatectomy, laparoscopic radical hilar cholangiocarcinoma resection, laparoscopic right trisegmentectomy, retroperitoneoscopic liver resection, retroperitoneoscopic pancreatic resection, single incision laparoscopic liver resection, and resection of huge tumor in the head of pancreas after ligation of abdominal vessels.
Daohong Chen is currently a USA citizen, and director of new drug discovery center/research institute of biological medicine at Yiling Pharmaceutical, Shijiazhuang/Beijing, China. He had done his MD, PhD (molecular pathology) degree from West China University of Medical Sciences. He did his postdoctoral trainings (cell biology and immunology) at University of Oxford, UK and Harvard Medical School, USA. He worked as a research faculty at Vanderbilt University Medical School and Indiana University Simon Cancer Center for 8 years. Besides, He was also a new drug discovery scientist in oncology at Eli Lilly and Company (USA) for 6 years. So far he had published 40 biomedical science-based articles in peer-reviewed journals. And his major scientific interest is treatment-associated cancer research.
Xiyun Deng received his M.S. and Ph.D. degree from Cancer Research Institute, Xiangya Medical College (now part of Central South University) in Pathophysiology/Cancer Biology in 1994 and 2006, respectively. He accepted his visiting scholarship at the NIH from 1997 to 1999. And completed his postdoctoral training at Wayne State University and Ohio State University between 2001 and 2005 and became a faculty member of the Translational Research Center at the University of Texas Health Science Center-Houston in 2010. He joined Hunan Normal University Medical College in 2012 and am currently full professor and Chair of the Department of Basic Medical Sciences.
His research interests focus on the molecular mechanisms of cancer metastasis and the experimental therapeutics targeting cancer stem cells. He is one of the originators of the new discovery that post-translational modifications of the chemokine receptor play a critical role in cancer metastasis. He have been the recipient of 3 research grants from the Natural Science Foundation of China (NSFC) and multiple grants from other funding agencies. And have published more than 60 peer-reviewed papers including first-author and/or corresponding-author articles/reviews in Blood, Clinical Cancer Research, Cancer Treatment Reviews, Oncotarget, International Journal of Cancer, and European Journal of Cancer. He is now editorial board member of several international peer-reviewed journals and serve as reviewers for the Natural Science Foundation of China and many domestic and international prestigious journals.